title: Temporal changes in the involvement of pyruvate dehydrogenase complex in muscle lactate accumulation during lipopolysaccharide infusion in rats.
abstract: A characteristic manifestation of sepsis is muscle lactate accumulation. This study examined any putative (causative) association between pyruvate dehydrogenase complex (PDC) inhibition and lactate accumulation in the extensor digitorum longus (EDL) muscle of rats infused with lipopolysaccharide (LPS), and explored the involvement of increased transcription of muscle-specific pyruvate dehydrogenase kinase (PDK) isoenzymes. Conscious, male Sprague-Dawley rats were infused i.v. with saline (0.4 ml h(-1), control) or LPS (150 mug kg(-1) h(-1)) for 2 h, 6 h or 24 h (n = 6-8). Muscle lactate concentration was elevated after 2, 6 and 24 h LPS infusion. Muscle PDC activity was the same at 2 h and 6 h, but was 65% lower after 24 h of LPS infusion (P < 0.01), when there was a 47% decrease in acetylcarnitine concentration (P < 0.05), and a 24-fold increase in PDK4 mRNA expression (P < 0.001). These changes were preceded by marked increases in tumour necrosis factor-alpha and interleukin-6 mRNA expression at 2 h. The findings indicate that the early (2 and 6 h) elevation in muscle lactate concentration during LPS infusion was not attributable to limited muscle oxygen availability or ATP production (evidenced by unchanged ATP and phosphocreatine (PCr) concentrations) or to PDC inhibition, whereas after 24 h, muscle lactate accumulation appears to have resulted from PDC activation status limiting pyruvate flux, most probably due to cytokine-mediated up-regulation of PDK4 transcription.
authors.affiliation: Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. nalamdar@bidmc.harvard.edu.
authors.forename: N
authors.initials: N
authors.lastname: Alamdari
authors.forename: D
authors.initials: D
authors.lastname: Constantin-Teodosiu
authors.forename: A J
authors.initials: AJ
authors.lastname: Murton
authors.forename: S M
authors.initials: SM
authors.lastname: Gardiner
authors.forename: T
authors.initials: T
authors.lastname: Bennett
authors.forename: R
authors.initials: R
authors.lastname: Layfield
authors.forename: P L
authors.initials: PL
authors.lastname: Greenhaff
mesh_terms: D000818:Animals; D007263:Infusions, Parenteral; D015850:Interleukin-6 / Q000378:metabolism*; D019344:Lactic Acid / Q000378:metabolism*; D008070:Lipopolysaccharides; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000378:metabolism*; D011768:Pyruvate Dehydrogenase Complex / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D018805:Sepsis / Q000139:chemically induced* / Q000378:metabolism*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
chemical_list: D015850:Interleukin-6; D008070:Lipopolysaccharides; D011768:Pyruvate Dehydrogenase Complex; D014409:Tumor Necrosis Factor-alpha; D019344:Lactic Acid